Hironobu Sasano

List of Publications by Year
in descending order

90 papers	11,736 citations	71061 41 h-index	48277 88 g-index
90 all docs	90 docs citations	90 times ranked	13923 citing authors

#	Article	IF	Citations
1	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Journal of Clinical Oncology, 2010, 28, 2784-2795.	0.8	2,667
2	Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. New England Journal of Medicine, 2017, 376, 2147-2159.	13.9	1,228
3	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version). Archives of Pathology and Laboratory Medicine, 2010, 134, e48-e72.	1.2	855
4	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology, 2018, 31, 1770-1786.	2.9	739
5	Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. Journal of Clinical Oncology, 2008, 26, 1059-1065.	0.8	409
6	The 2019 World Health Organization classification of tumours of the breast. Histopathology, 2020, 77, 181-185.	1.6	395
7	Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. Journal of Gastroenterology, 2010, 45, 234-243.	2.3	354
8	Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. Journal of Gastroenterology, 2015, 50, 58-64.	2.3	325
9	ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms. Neuroendocrinology, 2012, 95, 74-87.	1.2	294
10	Heterogeneous Increase in CD34-positive Alveolar Capillaries in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 1203-1208.	2.5	262
11	Dissecting human adrenal androgen production. Trends in Endocrinology and Metabolism, 2002, 13, 234-239.	3.1	260
12	Aromatase in Human Bone Tissue. Journal of Bone and Mineral Research, 1997, 12, 1416-1423.	3.1	239
13	Neuronal Pathway from the Liver Modulates Energy Expenditure and Systemic Insulin Sensitivity. Science, 2006, 312, 1656-1659.	6.0	233
14	Estrogen-Related Receptor Î± in Human Breast Carcinoma as a Potent Prognostic Factor. Cancer Research, 2004, 64, 4670-4676.	0.4	200
15	Liquid Chromatographyâ€“Tandem Mass Spectrometry Analysis of Human Adrenal Vein 19-Carbon Steroids Before and After ACTH Stimulation. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1182-1188.	1.8	193
16	Developmental changes in steroidogenic enzymes in human postnatal adrenal cortex: immunohistochemical studies. Clinical Endocrinology, 2000, 53, 739-747.	1.2	176
17	Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Human Pathology, 1994, 25, 530-535.	1.1	164
18	Intratumoral Aromatase in Human Breast, Endometrial, and Ovarian Malignancies*. Endocrine Reviews, 1998, 19, 593-607.	8.9	163

#	Article	IF	Citations
19	Sex steroid-producing enzymes in human breast cancer. Endocrine-Related Cancer, 2005, 12, 701-720.	1.6	156
20	Expression of the Steroid and Xenobiotic Receptor and Its Possible Target Gene, Organic Anion Transporting Polypeptide-A, in Human Breast Carcinoma. Cancer Research, 2006, 66, 535-542.	0.4	132
21	Aromatase Localization in Human Breast Cancer Tissues: Possible Interactions between Intratumoral Stromal and Parenchymal Cells. Cancer Research, 2007, 67, 3945-3954.	0.4	117
22	Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. Journal of Gastroenterology, 2007, 42, 497-500.	2.3	111
23	Temporal and spatial distribution of Corticosteroidogenic Enzymes Immunoreactivity in developing human adrenal. Molecular and Cellular Endocrinology, 2001, 174, 111-120.	1.6	98
24	New development in intracrinology of breast carcinoma. Breast Cancer, 2006, 13, 129-136.	1.3	86
25	In situ estrogen production and its regulation in human breast carcinoma: From endocrinology to intracrinology. Pathology International, 2009, 59, 777-789.	0.6	80
26	Urocortin Expression in Human Pituitary Gland and Pituitary Adenoma. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3842-3850.	1.8	79
27	Urocortin expression in the human central nervous system. Clinical Endocrinology, 1999, 50, 107-114.	1.2	74
28	Adrenal changes associated with adrenarche. Reviews in Endocrine and Metabolic Disorders, 2009, 10, 19-26.	2.6	74
29	Intracrinology of estrogens and androgens in breast carcinoma. Journal of Steroid Biochemistry and Molecular Biology, 2008, 108, 181-185.	1.2	73
30	Development of the human adrenal zona reticularis: morphometric and immunohistochemical studies from birth to adolescence. Journal of Endocrinology, 2009, 203, 241-252.	1.2	71
31	The intracrinology of breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2015, 145, 172-178.	1.2	61
32	JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. Journal of Gastroenterology, 2021, 56, 1033-1044.	2.3	58
33	Steroid Sulfotransferase 2A1 Gene Transcription Is Regulated by Steroidogenic Factor 1 and GATA-6 in the Human Adrenal. Molecular Endocrinology, 2005, 19, 184-197.	3.7	56
34	Immunohistochemical Study of Cytochrome b5 in Human Adrenal Gland and in Adrenocortical Adenomas from Patients with Cushing's Syndrome.. Endocrine Journal, 1998, 45, 89-95.	0.7	54
35	Analysis of Intrapulmonary Vessels and Epithelial-Endothelial Interactions in the Human Developing Lung. Laboratory Investigation, 2002, 82, 293-301.	1.7	52
36	Transcriptome Profiling Reveals Differentially Expressed Transcripts Between the Human Adrenal Zona Fasciculata and Zona Reticularis. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E518-E527.	1.8	49

#	Article	IF	Citations
37	Transcriptional Regulation of Dehydroepiandrosterone Sulfotransferase (SULT2A1) by Estrogen-Related Receptor Î±. Endocrinology, 2005, 146, 3605-3613.	1.4	47
38	Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: A possible androgenic bone protective effects induced by exemestane. Bone, 2007, 40, 876-887.	1.4	46
39	Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Research and Treatment, 2013, 142, 211-223.	1.1	45
40	Sex steroid receptors expression and hormoneâ€induced cell proliferation in human osteosarcoma. Cancer Science, 2008, 99, 518-523.	1.7	44
41	Analysis of Estrogen Receptor ?? and ?? in Endometrial Carcinomas: Correlation with ER?? and Clinicopathologic Findings in 45 Cases. International Journal of Gynecological Pathology, 2000, 19, 335-341.	0.9	42
42	Vasohibinâ€1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast. Cancer Science, 2010, 101, 1051-1058.	1.7	42
43	Aromatase in atherosclerotic lesions of human aorta. Journal of Steroid Biochemistry and Molecular Biology, 2001, 79, 67-74.	1.2	41
44	Activation of the Hypoxia Inducible Factor 1Î± Subunit Pathway in Steatotic Liver Contributes to Formation of Cholesterol Gallstones. Gastroenterology, 2017, 152, 1521-1535.e8.	0.6	40
45	KrÃ¼ppel-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens. Endocrine-Related Cancer, 2012, 19, 741-750.	1.6	39
46	<scp>OLFM</scp>4, <scp>LY</scp>6D and S100A7 as potent markers for distant metastasis in estrogen receptorâ€positive breast carcinoma. Cancer Science, 2018, 109, 3350-3359.	1.7	39
47	Characterization of messenger RNA expression of estrogen receptor-Î± and -Î² in patients with ovarian endometriosis. Fertility and Sterility, 2000, 73, 1219-1225.	0.5	34
48	BUB1 Immunolocalization in Breast Carcinoma: Its Nuclear Localization as a Potent Prognostic Factor of the Patients. Hormones and Cancer, 2013, 4, 92-102.	4.9	34
49	Aromatase in Human Breast Carcinoma as a Key Regulator of Intratumoral Sex Steroid Concentrations. Endocrine Journal, 2008, 55, 455-463.	0.7	32
50	Human adrenal cells that express both 3Î²-hydroxysteroid dehydrogenase type 2 (HSD3B2) and cytochrome b5 (CYB5A) contribute to adrenal androstenedione production. Journal of Steroid Biochemistry and Molecular Biology, 2011, 123, 122-126.	1.2	29
51	Functional pathology of human ovarian steroidogenesis: Normal cycling ovary and steroid-producing neoplasms. Endocrine Pathology, 1994, 5, 81-89.	5.2	28
52	Intratumoral estrogen production in breast carcinoma: significance of aromatase. Breast Cancer, 2008, 15, 270-277.	1.3	28
53	New Developments in Intracrinology of Human Breast Cancer. Annals of the New York Academy of Sciences, 2009, 1155, 76-79.	1.8	28
54	Controversies of aromatase localization in human breast cancerâ€"Stromal versus parenchymal cells. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 97-101.	1.2	27

#	Article	IF	Citations
55	Classification and Prognostic Stratification of Bronchopulmonary Neuroendocrine Neoplasms. Neuroendocrinology, 2020, 110, 393-403.	1.2	26
56	Body Fat Mass Is Associated With Ratio of Steroid Metabolites Reflecting 17,20-Lyase Activity in Prepubertal Girls. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4653-4660.	1.8	25
57	Aromatase in human liver and its diseases. Cancer Medicine, 2013, 2, 305-315.	1.3	20
58	Abnormal expression of miRâ€1 in breast carcinoma as a potent prognostic factor. Cancer Science, 2015, 106, 1642-1650.	1.7	20
59	Benign cortisol-secreting adrenocortical adenomas produce small amounts of androgens. Clinical Endocrinology, 2007, 66, 778-788.	1.2	19
60	TACC2 (transforming acidic coiledâ€coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferation. Cancer Medicine, 2016, 5, 1973-1982.	1.3	19
61	Roles of Aryl Hydrocarbon Receptor in Aromatase-Dependent Cell Proliferation in Human Osteoblasts. International Journal of Molecular Sciences, 2017, 18, 2159.	1.8	19
62	Clinicopathologic significance of immunostaining of Î±-thalassemia/mental retardation syndrome X-linked protein and death domainâ€“associated protein in neuroendocrine tumors. Human Pathology, 2013, 44, 2199-2203.	1.1	17
63	The Mediator Complex Subunit 1 Enhances Transcription of Genes Needed for Adrenal Androgen Production. Endocrinology, 2009, 150, 4145-4153.	1.4	16
64	Cytochrome 3A and 2E1 in human liver tissue: Individual variations among normal Japanese subjects. Life Sciences, 2010, 86, 393-401.	2.0	16
65	Estrogen-related receptor Î± in normal adrenal cortex and adrenocortical tumors: Involvement in development and oncogenesis. Molecular and Cellular Endocrinology, 2013, 365, 207-211.	1.6	16
66	GATA4 immunolocalization in breast carcinoma as a potent prognostic predictor. Cancer Science, 2014, 105, 600-607.	1.7	16
67	Minimal impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment era. Surgical Oncology, 2017, 26, 163-170.	0.8	16
68	ARHGAP15 in Human Breast Carcinoma: A Potent Tumor Suppressor Regulated by Androgens. International Journal of Molecular Sciences, 2018, 19, 804.	1.8	16
69	<scp>CITED</scp>2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance. Cancer Science, 2016, 107, 1898-1908.	1.7	15
70	Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis. Cancer Science, 2017, 108, 1510-1519.	1.7	14
71	Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts. Pancreatology, 2020, 20, 944-950.	0.5	14
72	From endocrinology to intracrinology. Endocrine Pathology, 1998, 9, 9-20.	5.2	13

#	Article	IF	Citations
73	Expression of AR, 5Î±R1 and 5Î±R2 in bladder urothelial carcinoma and relationship to clinicopathological factors. Life Sciences, 2017, 190, 15-20.	2.0	13
74	Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma. Endocrine-Related Cancer, 2012, 19, 485-496.	1.6	11
75	Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors. Cancers, 2022, 14, 775.	1.7	11
76	Aromatase inhibitor and bone. Biomedicine and Pharmacotherapy, 2007, 61, 540-542.	2.5	10
77	Novel classification based on immunohistochemistry combined with hierarchical clustering analysis in nonâ€functioning neuroendocrine tumor patients. Cancer Science, 2010, 101, 2278-2285.	1.7	10
78	Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases. Breast Cancer, 2021, 28, 915-926.	1.3	10
79	A novel liver metastasis-correlated protein of pancreatic neuroendocrine neoplasm (PanNEN) discovered by proteomic analysis. Oncotarget, 2018, 9, 24291-24303.	0.8	9
80	Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas. Breast Cancer Research and Treatment, 2016, 156, 45-55.	1.1	8
81	Forkhead Box I1 in Breast Carcinoma as a Potent Prognostic Factor. Acta Histochemica Et Cytochemica, 2021, 54, 123-130.	0.8	8
82	Immunolocalization of aromatase in human minor salivary glands of the lower lip with primary Sjogren's syndrome. Pathology International, 1998, 48, 786-790.	0.6	7
83	Characteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer. Journal of Clinical Pathology, 2020, 73, 147-153.	1.0	7
84	O6-methylguanine DNA methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms. BMC Cancer, 2020, 20, 1195.	1.1	4
85	Progesteron receptor expression in insulin producing cells of neuroendocrine neoplasms. Journal of Steroid Biochemistry and Molecular Biology, 2020, 201, 105694.	1.2	3
86	D-2-hydroxyglutarate dehydrogenase in breast carcinoma as a potent prognostic marker associated with proliferation. Histology and Histopathology, 2021, , 18362.	0.5	3
87	Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC. JTO Clinical and Research Reports, 2021, 2, 100150.	0.6	2
88	Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinomain situof the breast. Cancer Science, 2010, , .	1.7	1
89	New development in intracrinology of breast carcinoma: therapeutic horizons after aromatase inhibitors. Expert Review of Endocrinology and Metabolism, 2007, 2, 367-374.	1.2	0
90	Changing concepts of pancreatic neuroendocrine neoplasms: From WHO 2010 to WHO 2017. Suizo, 2019, 34, 56-62.	0.1	0